Product Description
Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus. At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum. Furthermore, dydrogesterone is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dydrogesterone#section=Pharmacology-and-Biochemistry)
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Myofibroma|Infertility, Male|Leiomyoma|Infertility, Female|Endometrial Cancer|Abortion, Threatened|Genital Diseases, Female|Obstetric Labor, Premature|Abortion, Spontaneous|Menopause|Pregnancy Outcomes|Infertility|Multiple Sclerosis
Phase 3: Menopause|Kidney Diseases|Endometrial Cancer|Uterine Cancer|Obstetric Labor, Premature|Bone Cancer|Infertility, Male|Infertility, Female|Pregnancy Outcomes|Weight Loss|Infertility|Anal Gland Cancer|Weight Gain|Abortion, Habitual|Abortion, Threatened|Vitamin A Deficiency|Pelvic Cancer|Drug Overdose|Stroke|Vaginal Cancer|Follicular Cyst|Vascular Cancer|Liver Cancer|Genital Cancer, Female|Hypertension, Renal|Protein Deficiency|Body Weight Changes|Muscle Cancer|Acute Respiratory Distress Syndrome|Male Breast Cancer|Pregnancy, Abdominal|Abortion, Spontaneous|Ovarian Cysts|Pregnancy, Ovarian
Phase 1: Pregnancy Outcomes|Pregnancy, Ovarian|Ovarian Cysts|Hyperandrogenism|Conduct Disorder|Follicular Cyst|Polycystic Ovary Syndrome|Infertility
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DPOS | N/A |
Recruiting |
Pregnancy, Ovarian|Pregnancy Outcomes|Obstetric Labor, Premature|Abortion, Threatened|Acute Respiratory Distress Syndrome |
2027-05-31 |
|
| CS-10459 | P4 |
Unknown Status |
Unknown |
2026-06-30 |
|
| ChiCTR2400089666 | N/A |
/Completed |
Immune Complex Diseases|Inflammation|Periodontal Pocket|Periodontal Diseases|Tooth Loss|Chronic Periodontitis |
2026-04-30 |
|
| ChiCTR2200064713 | N/A |
Not yet recruiting |
Abortion, Threatened |
2025-06-25 |